Fairmount Funds Management LLC 13D and 13G filings for Dianthus Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-25 9:00 pm Sale | 2025-11-21 | 13D | Dianthus Therapeutics, Inc. DNTH | Fairmount Funds Management LLC | 2,139,635 4.900% | -1,912,417 (-47.20%) | Filing |
| 2025-09-15 4:15 pm Purchase | 2025-09-11 | 13D | Dianthus Therapeutics, Inc. DNTH | Fairmount Funds Management LLC | 4,052,052 9.900% | 1,094,667 (+37.01%) | Filing |
| 2024-04-01 6:34 pm Sale | 2024-04-01 | 13D | Dianthus Therapeutics, Inc. DNTH | Fairmount Funds Management LLC | 2,957,385 9.990% | -3,362 (-0.11%) | Filing |
| 2024-01-24 5:26 pm Purchase | 2024-01-22 | 13D | Dianthus Therapeutics, Inc. DNTH | Fairmount Funds Management LLC | 2,960,747 9.900% | 1,086,914 (+58.00%) | Filing |
| 2023-09-21 4:32 pm Purchase | 2023-09-11 | 13D | Dianthus Therapeutics, Inc. DNTH | Fairmount Funds Management LLC | 1,873,833 12.700% | 1,873,833 (New Position) | Filing |